ARCADIA BIOSCIENCES INC (RKDA)
US0390143032 - Common Stock
Overall RKDA gets a fundamental rating of 3 out of 10. We evaluated RKDA against 90 industry peers in the Food Products industry. RKDA has a great financial health rating, but its profitability evaluates not so good. RKDA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RKDA had negative earnings in the past year.
In the past year RKDA has reported a negative cash flow from operations.
In the past 5 years RKDA always reported negative net income.
RKDA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -38.23%, RKDA is doing worse than 82.22% of the companies in the same industry.
The Return On Equity of RKDA (-56.64%) is worse than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.23% | ||
| ROE | -56.64% | ||
| ROIC | N/A |
ROA(3y)-52.5%
ROA(5y)-51.16%
ROE(3y)-76.39%
ROE(5y)-123.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 46.96%, RKDA belongs to the best of the industry, outperforming 97.78% of the companies in the same industry.
In the last couple of years the Gross Margin of RKDA has declined.
RKDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.48%
GM growth 5Y-3.26%
2. Health
2.1 Basic Checks
RKDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
RKDA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RKDA has been increased compared to 5 years ago.
There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RKDA has an Altman-Z score of -25.11. This is a bad value and indicates that RKDA is not financially healthy and even has some risk of bankruptcy.
RKDA has a Altman-Z score of -25.11. This is amonst the worse of the industry: RKDA underperforms 97.78% of its industry peers.
There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.11 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
A Current Ratio of 4.60 indicates that RKDA has no problem at all paying its short term obligations.
RKDA has a Current ratio of 4.60. This is amongst the best in the industry. RKDA outperforms 95.56% of its industry peers.
A Quick Ratio of 4.24 indicates that RKDA has no problem at all paying its short term obligations.
The Quick ratio of RKDA (4.24) is better than 96.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.6 | ||
| Quick Ratio | 4.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 77.87% over the past year.
The Revenue has decreased by -3.10% in the past year.
RKDA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.56% yearly.
EPS 1Y (TTM)77.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.06%
Revenue 1Y (TTM)-3.1%
Revenue growth 3Y-12.77%
Revenue growth 5Y29.56%
Sales Q2Q%-3.76%
3.2 Future
Based on estimates for the next years, RKDA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.25% on average per year.
RKDA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.27% yearly.
EPS Next Y91.83%
EPS Next 2Y38.61%
EPS Next 3Y23.25%
EPS Next 5YN/A
Revenue Next Year-16.75%
Revenue Next 2Y2.19%
Revenue Next 3Y6.27%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RKDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RKDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RKDA's earnings are expected to grow with 23.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.61%
EPS Next 3Y23.25%
5. Dividend
5.1 Amount
No dividends for RKDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARCADIA BIOSCIENCES INC
NASDAQ:RKDA (12/18/2024, 11:21:50 AM)
5.69
-0.21 (-3.56%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.74M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -38.23% | ||
| ROE | -56.64% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.96% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.6 | ||
| Quick Ratio | 4.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)77.87%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y91.83%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-3.1%
Revenue growth 3Y-12.77%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y